Prolactin-lowering effect of luteinizing hormone-releasing hormone agonist administration in prolactinoma patients

Miguel A. Rubio, Jose A. Cabranes, Andrew V. Schally, Aniceto L. Charro

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

We studied the effect of LHRH agonist administration on serum PRL levels in five women with microprolactinomas and two women and a man with intrasellar macroprolactinomas. Each patient received either D-Trp6-LHRH or buserelin for 90 days. Serum PRL levels decreased significantly in the patients with microprolactinomas by 65%, from 156 ± 93 (± SD) to 54 ± 49 μg/L on day 90 (P = 0.011), but it did not decrease in the macroprolactinoma patients. Mean serum LH and FSH decreased by 43% and 62.5%, respectively, in all eight patients. There was no statistically significant correlation between the serum PRL and LH or FSH levels in the microprolactinoma patients. We conclude that LHRH agonists can counteract the hyperprolactinemia produced by microprolactinomas and that the effect probably is not exerted by an action on the gonadotrophs.

Original languageEnglish (US)
Pages (from-to)444-447
Number of pages4
JournalJournal of Clinical Endocrinology and Metabolism
Volume69
Issue number2
DOIs
StatePublished - Aug 1989
Externally publishedYes

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Fingerprint Dive into the research topics of 'Prolactin-lowering effect of luteinizing hormone-releasing hormone agonist administration in prolactinoma patients'. Together they form a unique fingerprint.

  • Cite this